Navigation Links
Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
Date:3/16/2009

SEATTLE, March 16, /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 8th Annual WBBA Invest Northwest Conference on Wednesday, March 18th at 10:10 AM in the Harbor Dining Room of the Bell Harbor Conference Center.

The presentation will also be webcast live with slides, and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.

                          WBBA Invest Northwest Conference
                    CTI Presentation: Wednesday, March 18, 2009
                        10:10 AM PST/1:10 PM EST/6:10 PM CET
                Harbor Dining Room, Bell Harbor Conference Center
              Audio webcast with slides at www.celltherapeutics.com

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , Dec. ... BCLI ), a leading developer of adult stem ... subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a grant ... Office of the Chief Scientist (OCS).  This is ... of grant support from the Office of the Chief ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... SupraNet Communications, Inc. , an Internet service provider, ... infrastructure, allowing them to provide Internet services to businesses ... options. , ,The new OC12 from Charter Business ... businesses throughout the southern half of state where Charter ...
... write about these days stirs as much feedback as my ... blog tools, search, social networks, and syndication technologies. , ,Over ... of social networks to a cautious blogger, and now an ... disruptive force that is fundamentally changing communications on every facet. ...
... has received a $500,000 federal research grant, the ... II small-business innovation research grant from the National ... treatment. The funding complements the $100,000 phase I grant ... , ,According to Sal Braico, ConjuGons chief operating officer, ...
Cached Biology Technology:Rural Wisconsin businesses gain high-speed net access 2Changing perspectives on social networks 2Changing perspectives on social networks 3ConjuGon receives $500,000 to battle bacteria 2
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... 2014   Atmel® Corporation (NASDAQ: ... touch technology solutions, today launched the industry,s first family ... widest V cc range from 1.7V to 5.5V. ... I 2 C bus communication speeds, and are available ... them ideal for consumer, industrial, computer, and medical applications. ...
(Date:11/18/2014)... Nov. 18, 2014   EyeLock Inc. , ... and MorphoTrust USA (Safran), a leading ... announced a strategic partnership to offer comprehensive biometric ... administration (MVA), airport screening and financial services markets. ... MorphoTrust serves consumers through a nationwide network of ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... Reproductive medicine is one of today,s most exciting ... of medical ,firsts, new rulings by regulatory bodies or ... in the field, ethicists, legislators, the media and the ... All sessions are open to journalists and registration is ...
... It might sound like a mashup of monster movies, ... attacked its prey, reconstructing a killing that took place 4 ... is incredibly rare, but by careful, forensic-style analysis of bite ... based in Pisa, Italy, have reconstructed the events that led ...
... , This release is available in French . ... Dr. Hanadi Sleiman has achieved a major breakthrough in the development ... drugs to specific diseased cells. Sleiman explains that the research involves ... used as the genetic code for life, it becomes a kind ...
Cached Biology News:ESHRE Annual Meeting, June 27-30 in Rome 2Jaws -- 4 million B.C. 2
...
... Product Rabbit polyclonal to JNK1 (phospho T183 ... to an internal domain containing phosphorylated T183/Y185. ... and Rat. Not yet tested in other species. ... several subgroups, including the ERK, JNK, and p38 ...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... solid. Increases the expression of glutathione peroxidase. ... 2 O. Unstable in aqueous solutions; reconstitute ... 3211-76-5, M.W. 196.1. References: Merck Index ... A.F. 1995. Biochem. J. 306, ...
Biology Products: